Prosight Management LP Sells 1,187,740 Shares of Shattuck Labs, Inc. $STTK

Prosight Management LP trimmed its position in Shattuck Labs, Inc. (NASDAQ:STTK) by 17.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,451,195 shares of the company’s stock after selling 1,187,740 shares during the quarter. Shattuck Labs makes up approximately 3.0% of Prosight Management LP’s portfolio, making the stock its 14th biggest holding. Prosight Management LP owned approximately 11.38% of Shattuck Labs worth $13,028,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of STTK. Turtle Creek Wealth Advisors LLC bought a new position in Shattuck Labs in the 3rd quarter valued at $29,000. Pinnacle Associates Ltd. grew its position in shares of Shattuck Labs by 1.8% during the 3rd quarter. Pinnacle Associates Ltd. now owns 1,388,723 shares of the company’s stock valued at $3,319,000 after purchasing an additional 25,000 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Shattuck Labs by 265.4% in the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after purchasing an additional 31,355 shares during the period. 683 Capital Management LLC raised its position in shares of Shattuck Labs by 4.3% in the second quarter. 683 Capital Management LLC now owns 1,095,000 shares of the company’s stock worth $867,000 after buying an additional 45,000 shares in the last quarter. Finally, Bridgeway Capital Management LLC raised its position in shares of Shattuck Labs by 147.5% in the second quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock worth $73,000 after buying an additional 55,000 shares in the last quarter. Institutional investors own 58.74% of the company’s stock.

Shattuck Labs Trading Down 2.3%

Shares of Shattuck Labs stock opened at $5.99 on Friday. The firm has a market capitalization of $428.64 million, a PE ratio of -7.78 and a beta of 1.55. The business’s 50-day moving average price is $4.41 and its 200-day moving average price is $3.00. Shattuck Labs, Inc. has a 12 month low of $0.69 and a 12 month high of $6.25.

Shattuck Labs (NASDAQ:STTK) last released its earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12). The firm had revenue of ($1.00) million during the quarter, compared to the consensus estimate of $0.17 million. As a group, analysts predict that Shattuck Labs, Inc. will post -1.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

STTK has been the subject of several research analyst reports. Needham & Company LLC assumed coverage on Shattuck Labs in a research note on Friday, March 6th. They set a “buy” rating and a $25.00 price objective for the company. Citigroup raised their price target on Shattuck Labs from $4.00 to $7.00 and gave the company a “neutral” rating in a report on Friday. HC Wainwright upgraded Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 price target for the company in a research report on Monday, December 1st. TD Cowen reissued a “buy” rating on shares of Shattuck Labs in a report on Friday, March 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Shattuck Labs in a research report on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.50.

Shattuck Labs Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.